NCT05047848Unknown不适用
Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer
Liaoning Tumor Hospital & Institute1 个研究点 分布在 1 个国家目标入组 82 人开始时间: 2021年8月18日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 82
- 试验地点
- 1
- 主要终点
- Overall Response Rate (ORR)
研究概览
简要总结
This is a Open-label study of chidamide in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, Her2 negative, advanced breast cancer who have received no or only one line of endocrine therapy for advanced breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •women aged ≥ 18 years, histologically or cytologically confirmed HR positive (ER expression ≥ 10%, PR positive or negative), HER2 negative breast cancer patients;
- •before enrollment for unresectable locally advanced or metastatic breast cancer, and at least one measurable lesion or no measurable lesion and bone metastasis alone patients;
- •For locally advanced or metastatic breast cancer, no previous endocrine therapy or first-line endocrine therapy, and no previous use of CDK4/6 inhibitors. Specifically, it includes the following conditions:
- •Cohort 1: (neo) recurrence > 12 months after the end of adjuvant endocrine therapy, and without any rescue therapy · newly diagnosed advanced breast cancer without any rescue therapy Cohort 2: (neo) recurrence during or ≤ 12 months after the completion of adjuvant endocrine therapy, and without any rescue therapy · recurrence > 12 months after the completion of adjuvant endocrine therapy, and progression by first-line endocrine therapy · newly diagnosed advanced breast cancer and progression by first-line endocrine rescue therapy
- •Cohort 1 without previous chemotherapy for advanced breast cancer; Cohort 2 with ≤ 1 previous chemotherapy for advanced breast cancer;
- •no brain metastasis or asymptomatic brain metastasis;
- •ECOG score 0-1;
- •Absolute neutrophil count ≥ 1.5 × 109/L, platelet ≥ 100 × 109/L, hemoglobin ≥ 90 g/L;
- •Expected survival time ≥ 3 months;
- •Voluntarily participate in this clinical trial, sign the written informed consent;
排除标准
- •no measurable lesions (except bone metastases alone), such as pleural or pericardial exudates, ascites, etc.
- •Patients who have undergone major surgical procedures or significant trauma before enrollment, or are expected to undergo major surgical treatment
- •Patients who have previously been treated with CDK4/6 inhibitors, fulvestrant or HDAC inhibitors (including romidepsin, vorinostat, berlistat, parabrestat), but have received 1 cycle (≤ 2 times, on d1, d15, respectively) of fulvestrant within 28 days (before enrollment) are allowed
- •Known history of allergy to the drug components of this protocol
- •Meningeal metastasis before enrollment
- •Uncontrollable serosal effusion
- •Active infection [an active bacterial, viral, fungal, mycobacterial, parasitic or other infection (excluding fungal infections of the nail bed) within 4 months prior to Screening or any major infectious event requiring intravenous antibiotics, or targeted antiviral therapy, or hospitalization], or persistent fever within 14 days prior to Screening
- •a history of immunodeficiency, including HIV test positive, or suffering from other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;
- •according to the investigator's judgment, there are serious hazards to the patient's safety, or affect the patient to complete the study of concomitant diseases (such as: severe hypertension, diabetes, thyroid disease, active infection, etc.);
- •History of definite neurological or psychiatric disorders, including epilepsy or dementia
- •Subjects who, in the opinion of the investigator, are not suitable for the study
研究组 & 干预措施
chidamide + fulvestrant
Experimental
干预措施: Chidamide (Drug)
chidamide + fulvestrant
Experimental
干预措施: Fulvestrant (Drug)
结局指标
主要结局
Overall Response Rate (ORR)
时间窗: Up to approximately 26 months
Overall response rate (ORR) is defined as the proportion of patients with the best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1.
次要结局
- Clinical Benefit Rate (CBR)(Up to approximately 26 months)
- Progression Free Survival (PFS)(Up to approximately 26 months)
- Duration of Response (DOR)(Up to approximately 26 months)
- Overall Survival (OS)(Up to approximately 58 months)
研究者
Tao Sun
Director
Liaoning Tumor Hospital & Institute
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 InhibitorsBreast CancerNCT05191914Liaoning Tumor Hospital & Institute20
尚未招募
2 期
A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal CancerAdvanced Esophageal CarcinomaNCT06745193Peking University63
Unknown
2 期
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell LymphomaDiffuse Large B-cell LymphomaNCT02733380Henan Cancer Hospital20
尚未招募
2 期
Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast CancerHormone Receptor-positive Advanced Breast CancerNCT05808582The First Affiliated Hospital with Nanjing Medical University60
已完成
3 期
Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast CancerBreast CancerNCT02482753Chipscreen Biosciences, Ltd.365